FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060087636> ?p ?o ?g. }

• W2060087636 endingPage "366.e1" @default.
• W2060087636 startingPage "355" @default.
• W2060087636 abstract "Background & AimsTwenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.MethodsPatients with HCV genotype 2 or 3 infection (n = 151), enrolled at research centers in North America, Europe, or Australia, were assigned randomly to groups given 12 or 16 weeks of daclatasvir (60 mg once daily), or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin. Treatment was extended to 24 weeks for recipients of daclatasvir who did not meet the criteria for early virologic response. The primary end point was SVR at 24 weeks after treatment (SVR24).ResultsBaseline characteristics were similar among patients within each HCV genotype group. However, the 80 patients with HCV genotype 3, compared with the 71 patients with HCV genotype 2, were younger (mean age, 45 vs 53 y, respectively), and a larger proportion had cirrhosis (23% vs 1%, respectively). Among patients with HCV genotype 2 infection, an SVR24 was achieved by 83%, 83%, and 63% of those in the daclatasvir 12-week group, the daclatasvir 16-week group, or the placebo group, respectively; among patients with HCV genotype 3 infection, an SVR24 was achieved by 69%, 67%, and 59% of patients in these groups, respectively. Differences between genotypes largely were attributable to the higher frequency of post-treatment relapse among patients infected with HCV genotype 3. In both daclatasvir arms for both HCV genotypes, the lower bound of the 80% confidence interval of the difference in SVR24 rates between the daclatasvir and placebo arms was above –20%, establishing noninferiority. Safety findings were similar among groups, and were typical of those expected from peginterferon alfa and ribavirin therapy.ConclusionsTwelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Clinicaltrials.gov number: NCT01257204. Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. Patients with HCV genotype 2 or 3 infection (n = 151), enrolled at research centers in North America, Europe, or Australia, were assigned randomly to groups given 12 or 16 weeks of daclatasvir (60 mg once daily), or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin. Treatment was extended to 24 weeks for recipients of daclatasvir who did not meet the criteria for early virologic response. The primary end point was SVR at 24 weeks after treatment (SVR24). Baseline characteristics were similar among patients within each HCV genotype group. However, the 80 patients with HCV genotype 3, compared with the 71 patients with HCV genotype 2, were younger (mean age, 45 vs 53 y, respectively), and a larger proportion had cirrhosis (23% vs 1%, respectively). Among patients with HCV genotype 2 infection, an SVR24 was achieved by 83%, 83%, and 63% of those in the daclatasvir 12-week group, the daclatasvir 16-week group, or the placebo group, respectively; among patients with HCV genotype 3 infection, an SVR24 was achieved by 69%, 67%, and 59% of patients in these groups, respectively. Differences between genotypes largely were attributable to the higher frequency of post-treatment relapse among patients infected with HCV genotype 3. In both daclatasvir arms for both HCV genotypes, the lower bound of the 80% confidence interval of the difference in SVR24 rates between the daclatasvir and placebo arms was above –20%, establishing noninferiority. Safety findings were similar among groups, and were typical of those expected from peginterferon alfa and ribavirin therapy. Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Clinicaltrials.gov number: NCT01257204." @default.
• W2060087636 created "2016-06-24" @default.
• W2060087636 creator A5004178749 @default.
• W2060087636 creator A5004741643 @default.
• W2060087636 creator A5005099163 @default.
• W2060087636 creator A5005950789 @default.
• W2060087636 creator A5006799687 @default.
• W2060087636 creator A5009847961 @default.
• W2060087636 creator A5011865871 @default.
• W2060087636 creator A5024039879 @default.
• W2060087636 creator A5025317574 @default.
• W2060087636 creator A5033485067 @default.
• W2060087636 creator A5042678528 @default.
• W2060087636 creator A5044841082 @default.
• W2060087636 creator A5046730718 @default.
• W2060087636 creator A5047697581 @default.
• W2060087636 creator A5048237873 @default.
• W2060087636 creator A5052909853 @default.
• W2060087636 creator A5059586370 @default.
• W2060087636 creator A5062593266 @default.
• W2060087636 creator A5065724405 @default.
• W2060087636 creator A5075322332 @default.
• W2060087636 creator A5076282431 @default.
• W2060087636 creator A5076355159 @default.
• W2060087636 creator A5084483277 @default.
• W2060087636 creator A5085357579 @default.
• W2060087636 creator A5087714251 @default.
• W2060087636 creator A5089037721 @default.
• W2060087636 creator A5089047789 @default.
• W2060087636 date "2015-02-01" @default.
• W2060087636 modified "2023-09-30" @default.
• W2060087636 title "Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection" @default.
• W2060087636 cites W1892624833 @default.
• W2060087636 cites W1913786670 @default.
• W2060087636 cites W1968761860 @default.
• W2060087636 cites W1980771473 @default.
• W2060087636 cites W1983369983 @default.
• W2060087636 cites W1989606118 @default.
• W2060087636 cites W1995591620 @default.
• W2060087636 cites W2023852707 @default.
• W2060087636 cites W2039979336 @default.
• W2060087636 cites W2042695929 @default.
• W2060087636 cites W2044203022 @default.
• W2060087636 cites W2065054658 @default.
• W2060087636 cites W2066172848 @default.
• W2060087636 cites W2075282196 @default.
• W2060087636 cites W2078251659 @default.
• W2060087636 cites W2100577226 @default.
• W2060087636 cites W2111614585 @default.
• W2060087636 cites W2112876622 @default.
• W2060087636 cites W2113864802 @default.
• W2060087636 cites W2120733999 @default.
• W2060087636 cites W2121209352 @default.
• W2060087636 cites W2125065061 @default.
• W2060087636 cites W2125963799 @default.
• W2060087636 cites W2143559032 @default.
• W2060087636 cites W2154658415 @default.
• W2060087636 doi "https://doi.org/10.1053/j.gastro.2014.10.007" @default.
• W2060087636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25311593" @default.
• W2060087636 hasPublicationYear "2015" @default.
• W2060087636 type Work @default.
• W2060087636 sameAs 2060087636 @default.
• W2060087636 citedByCount "51" @default.
• W2060087636 countsByYear W20600876362015 @default.
• W2060087636 countsByYear W20600876362016 @default.
• W2060087636 countsByYear W20600876362017 @default.
• W2060087636 countsByYear W20600876362018 @default.
• W2060087636 countsByYear W20600876362019 @default.
• W2060087636 countsByYear W20600876362021 @default.
• W2060087636 countsByYear W20600876362022 @default.
• W2060087636 countsByYear W20600876362023 @default.
• W2060087636 crossrefType "journal-article" @default.
• W2060087636 hasAuthorship W2060087636A5004178749 @default.
• W2060087636 hasAuthorship W2060087636A5004741643 @default.
• W2060087636 hasAuthorship W2060087636A5005099163 @default.
• W2060087636 hasAuthorship W2060087636A5005950789 @default.
• W2060087636 hasAuthorship W2060087636A5006799687 @default.
• W2060087636 hasAuthorship W2060087636A5009847961 @default.
• W2060087636 hasAuthorship W2060087636A5011865871 @default.
• W2060087636 hasAuthorship W2060087636A5024039879 @default.
• W2060087636 hasAuthorship W2060087636A5025317574 @default.
• W2060087636 hasAuthorship W2060087636A5033485067 @default.
• W2060087636 hasAuthorship W2060087636A5042678528 @default.
• W2060087636 hasAuthorship W2060087636A5044841082 @default.
• W2060087636 hasAuthorship W2060087636A5046730718 @default.
• W2060087636 hasAuthorship W2060087636A5047697581 @default.
• W2060087636 hasAuthorship W2060087636A5048237873 @default.
• W2060087636 hasAuthorship W2060087636A5052909853 @default.
• W2060087636 hasAuthorship W2060087636A5059586370 @default.
• W2060087636 hasAuthorship W2060087636A5062593266 @default.
• W2060087636 hasAuthorship W2060087636A5065724405 @default.
• W2060087636 hasAuthorship W2060087636A5075322332 @default.
• W2060087636 hasAuthorship W2060087636A5076282431 @default.
• W2060087636 hasAuthorship W2060087636A5076355159 @default.
• W2060087636 hasAuthorship W2060087636A5084483277 @default.
• W2060087636 hasAuthorship W2060087636A5085357579 @default.
• W2060087636 hasAuthorship W2060087636A5087714251 @default.
• W2060087636 hasAuthorship W2060087636A5089037721 @default.

• next